A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects with Selected Advanced Solid Tumors
This is a first-time-in-human (FTiH) Phase 1, multicenter, open-label, dose-escalation, and dose-expansion study of MEDI0562 to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity in adult subjects with selected advanced solid tumors.
* Subjects must have confirmed recurrent or metastatic solid tumor that is deemed to be incurable by local therapy. Subjects with recurrent disease who have had disease progression after curative treatment for locoregionally advanced disease are eligible. Subjects must have progressive disease and may have received up to 4 prior systemic treatment regimens including both standard of care and investigational therapies. Subjects with recurrent disease may have received prior systemic therapy as part of induction, chemoradiotherapy, or adjuvant chemotherapy for potential curative treatment.
* Subjects must have at least 1 measurable lesion.
Multiple Tumor Types
Rom Leidner, M.D.
- Oncology and Hematology Care Eastside